2160   GNI Group Ltd.

04/05/2024 16:00	Corporate Governance Report
02/14/2024 16:20	Consolidated Financial Results for FY2023 (IFRS)
11/14/2023 08:45	Gyre Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
11/06/2023 10:20	GNI Group Updates Full Year 2023 Consolidated Earnings Forecast
10/31/2023 15:45	Gyre Therapeutics assigns $5Million worth of preferred shares and warrants to GNI USA
10/31/2023 10:20	GNI Group Completes the Transaction with Catalyst Biosciences
10/31/2023 10:20	Name change from Catalyst Biosciences to Gyre Therapeutics
10/27/2023 10:00	Catalyst Biosciences Files 2023Q3 Financial Statements
10/26/2023 10:00	Subject Enrollment Completed in F351 Phase III Clinical Trial
10/24/2023 13:46	Frequently Asked Questions and Answers on The Transaction between Catalyst Biosciences and GNI Group
10/24/2023 09:30	Disclosure by Catalyst Biosciences on The Transaction with GNI Group
10/23/2023 10:20	China Securities Regulatory Commission's Approval Status on the Transaction Between CBIO and Beijing Continent
10/16/2023 15:08	Latest Status on the Transaction with Catalyst Biosciences, Inc.
09/28/2023 16:10	GNI Group's New Management Structure
09/22/2023 13:30	F351 Presentation in An Academic Conference in the United States
09/15/2023 13:00	On Kaisha Shikihou Article
09/12/2023 17:15	Notice Concerning Finalized Issuance of Stock Acquisition Rights (Paid Stock Options)
09/04/2023 10:15	Frequently Asked Questions and Answers
09/01/2023 11:10	A Research Paper on F351 Is Published
09/01/2023 09:36	Catalyst Biosciences, Inc. Files 8-K on Its Stockholder Meeting Results
08/28/2023 18:15	Notice on Stock Acquisition Rights (Paid Stock Options) Issuance
08/25/2023 14:00	Frequently Asked Questions and Answers
08/22/2023 13:31	(Update to a previous disclosure) Consolidated Subsidiary Cullgen Closes Series C Funding
08/21/2023 09:30	Summary of FY2023Q2 Analyst Meeting Q&A
08/18/2023 09:50	(Update to a previous disclosure) F351 Phase II Clinical Trial Research Paper Selected in China's Top 10 Original Research
08/18/2023 09:30	(Update to a previous disclosure) F351 Phase III Clinical Trial Status
08/17/2023 13:30	FY2023Q2 Factbook
08/16/2023 13:30	Q2 FY2023 Financial Results Corporate Presentation
08/15/2023 08:30	Catalyst Biosciences, Inc. Files 2023Q2 Financial Statements
08/14/2023 16:00	(Update to a previous disclosure) F351 Phase III Clinical Trial Status
08/14/2023 16:00	Consolidated Financial Results for Q2 FY2023(IFRS)
08/04/2023 16:30	Notice Concerning Finalized Issuance of Stock Acquisition Rights (Paid Stock Options)
08/03/2023 13:35	GNI Group Updates Full Year 2023 Consolidated Earnings Forecast
08/01/2023 16:00	GNI Group Invests in Shanghai JIUCE Medical Device Technology Co., Ltd to Expand Its Biomaterial Business in China
07/20/2023 16:00	Notice on Stock Acquisition Rights (Paid Stock Options) Issuance
07/03/2023 15:00	Notice of Executive Officer Appointment
07/03/2023 15:00	Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status
06/15/2023 15:43	GNI's Subsidiary Cullgen Enters into Strategic Collaboration and Option Agreement with Astellas to Advance Innovative Targeted Protein Degraders
06/01/2023 15:00	Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status
05/17/2023 17:30	Q1 FY2023 Financial Results Corporate Presentation
05/15/2023 15:04	Consolidated Financial Results for Q1 FY2023(IFRS)
05/01/2023 15:00	Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status